SI3471780T1 - Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom - Google Patents

Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom

Info

Publication number
SI3471780T1
SI3471780T1 SI201730553T SI201730553T SI3471780T1 SI 3471780 T1 SI3471780 T1 SI 3471780T1 SI 201730553 T SI201730553 T SI 201730553T SI 201730553 T SI201730553 T SI 201730553T SI 3471780 T1 SI3471780 T1 SI 3471780T1
Authority
SI
Slovenia
Prior art keywords
aflibercept
aav2
sdm
version
treatment
Prior art date
Application number
SI201730553T
Other languages
English (en)
Slovenian (sl)
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies, Inc. filed Critical Adverum Biotechnologies, Inc.
Publication of SI3471780T1 publication Critical patent/SI3471780T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
SI201730553T 2016-06-16 2017-06-16 Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom SI3471780T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept
EP17814223.8A EP3471780B1 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number Publication Date
SI3471780T1 true SI3471780T1 (sl) 2021-03-31

Family

ID=60663653

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201730553T SI3471780T1 (sl) 2016-06-16 2017-06-16 Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom
SI201731629T SI3795181T1 (sl) 2016-06-16 2017-06-16 Zdravljenje amd z uporabo variante aav2 z afliberceptom

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201731629T SI3795181T1 (sl) 2016-06-16 2017-06-16 Zdravljenje amd z uporabo variante aav2 z afliberceptom

Country Status (25)

Country Link
US (2) US20190151409A1 (cg-RX-API-DMAC7.html)
EP (3) EP4671369A2 (cg-RX-API-DMAC7.html)
JP (5) JP6814822B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210021113A (cg-RX-API-DMAC7.html)
CN (2) CN109641065A (cg-RX-API-DMAC7.html)
AU (3) AU2017286673B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018076124A2 (cg-RX-API-DMAC7.html)
CA (1) CA3027737A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123697T1 (cg-RX-API-DMAC7.html)
DK (2) DK3471780T3 (cg-RX-API-DMAC7.html)
ES (2) ES2840059T3 (cg-RX-API-DMAC7.html)
FI (1) FI3795181T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201842T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051953T2 (cg-RX-API-DMAC7.html)
IL (3) IL279919B2 (cg-RX-API-DMAC7.html)
LT (2) LT3471780T (cg-RX-API-DMAC7.html)
MX (2) MX391779B (cg-RX-API-DMAC7.html)
PL (1) PL3795181T3 (cg-RX-API-DMAC7.html)
PT (2) PT3471780T (cg-RX-API-DMAC7.html)
RS (2) RS67328B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201811232XA (cg-RX-API-DMAC7.html)
SI (2) SI3471780T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100010T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017218974A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808538B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
RS67328B1 (sr) * 2016-06-16 2025-11-28 Adverum Biotechnologies Inc Lečenje amd-a korišćenjem aav2 varijante sa afliberceptom
EP3528785A4 (en) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. MODIFIED AAV CASPIDS AND USES THEREOF
US11773406B2 (en) 2017-03-17 2023-10-03 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CA3079565A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
UA127831C2 (uk) * 2017-11-27 2024-01-17 4Д Молекьюлар Терапьютикс Інк. Капсид аденоасоційованого вірусу та його застосування для інгібування ангіогенезу
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
WO2019198084A1 (en) * 2018-04-12 2019-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US20200297869A1 (en) * 2019-03-04 2020-09-24 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
CA3137284A1 (en) * 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
JP2023509263A (ja) * 2019-09-11 2023-03-08 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法
AU2020345915A1 (en) * 2019-09-11 2022-03-24 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
TWI819268B (zh) 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
JP2023540464A (ja) * 2020-07-21 2023-09-25 インスピラール リミテッド 眼疾患の処置のための組成物および方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
MX2023002695A (es) * 2020-09-03 2023-05-19 Univ Massachusetts Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo.
CA3197936A1 (en) 2020-12-01 2022-06-09 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
US20240197915A1 (en) * 2021-04-27 2024-06-20 Adverum Biotechnologies, Inc. Methods of treating ocular diseases using aav2 variants encoding aflibercept
TW202342526A (zh) 2022-02-21 2023-11-01 大陸商上海瑞宏迪醫藥有限公司 Ｖｅｇｆ結合分子及其醫藥用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638342T3 (es) * 2011-04-22 2017-10-19 The Regents Of The University Of California Viriones de virus adenoasociado con cápside variante y métodos para su uso
PT2846836T (pt) * 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150111275A1 (en) * 2012-06-11 2015-04-23 Daniel V. Palanker Optical regulation of gene expression in the retina
KR20230152151A (ko) * 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
MY187898A (en) * 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
RS67328B1 (sr) * 2016-06-16 2025-11-28 Adverum Biotechnologies Inc Lečenje amd-a korišćenjem aav2 varijante sa afliberceptom

Also Published As

Publication number Publication date
KR102218265B1 (ko) 2021-02-25
SMT202100010T1 (it) 2021-03-15
EP3795181B1 (en) 2025-08-06
HUE051953T2 (hu) 2021-04-28
CN117531025A (zh) 2024-02-09
RS61311B1 (sr) 2021-02-26
PT3471780T (pt) 2020-12-17
SI3795181T1 (sl) 2025-11-28
IL263686B (en) 2021-02-28
ES2840059T3 (es) 2021-07-06
HRP20201842T1 (hr) 2021-04-16
IL314568B2 (en) 2025-09-01
EP3471780A4 (en) 2019-04-24
AU2021225178A1 (en) 2021-09-30
PL3795181T3 (pl) 2025-12-22
ES3049818T3 (en) 2025-12-18
CN109641065A (zh) 2019-04-16
IL279919B2 (en) 2025-01-01
CA3027737A1 (en) 2017-12-21
AU2025202930A1 (en) 2025-05-15
WO2017218974A3 (en) 2018-01-25
WO2017218974A2 (en) 2017-12-21
RS67328B1 (sr) 2025-11-28
DK3795181T3 (da) 2025-10-13
CY1123697T1 (el) 2022-03-24
EP4671369A2 (en) 2025-12-31
JP2022137244A (ja) 2022-09-21
BR112018076124A2 (pt) 2019-03-26
IL279919B1 (en) 2024-09-01
IL314568A (en) 2024-09-01
JP2024113193A (ja) 2024-08-21
SMT202500400T1 (it) 2025-11-10
LT3795181T (lt) 2025-12-29
AU2017286673B2 (en) 2021-06-24
LT3471780T (lt) 2021-01-25
US20220265740A1 (en) 2022-08-25
AU2017286673A1 (en) 2019-01-31
JP2020203941A (ja) 2020-12-24
JP6814822B2 (ja) 2021-01-20
KR20190037228A (ko) 2019-04-05
SG11201811232XA (en) 2019-01-30
AU2021225178B2 (en) 2025-01-30
FI3795181T3 (fi) 2025-10-14
MX2018015512A (es) 2019-04-24
JP2019521990A (ja) 2019-08-08
MX391779B (es) 2025-03-21
KR20210021113A (ko) 2021-02-24
IL263686A (en) 2019-01-31
IL314568B1 (en) 2025-05-01
ZA201808538B (en) 2021-04-28
PT3795181T (pt) 2025-11-05
EP3471780A2 (en) 2019-04-24
MX2022004786A (es) 2022-05-16
JP2025186377A (ja) 2025-12-23
DK3471780T3 (da) 2020-11-23
EP3795181A1 (en) 2021-03-24
IL279919A (en) 2021-03-01
US20190151409A1 (en) 2019-05-23
EP3471780B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
SI3471780T1 (sl) Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
DK4050034T3 (da) Cd3-bindende antistoffer
EP3458034A4 (en) POLYNUCLEOTIDES ENCODING RELAXIN
IL256562A (en) Humanized or chimeric cd3 antibodies
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
PL3265053T3 (pl) Sposoby leczenia skóry
DK3474802T3 (da) Medicinsk forbinding
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
PL3612624T3 (pl) Terapia genowa
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3373874T3 (da) Medicinsk forbinding
PL3612237T3 (pl) Terapia genowa
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
EP3630331C0 (en) FLUID TREATMENT
DK3302478T3 (da) Pac-1 kombinations behandling
EP3925642C0 (en) SYRINGE STABILIZER
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
KR20180084928A (ko) 특히 전류의 도움으로 인간 케라틴 물질을 처리하기 위한 디바이스
EP3800199C0 (en) H3.3 CTL PEPTIDES AND THEIR USES
EP3631005A4 (en) Serial electrophoresis
LT3290436T (lt) Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui
DK3250168T3 (da) Forbedringer vedrørende nethindebehandling